TLC-6740 + tirzepatide

**TLC-6740 + tirzepatide** is an investigational, all-oral combination therapy consisting of TLC-6740—a liver-targeted mitochondrial protonophore—and tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 receptor (GLP-1R) agonist. TLC-6740 is designed to increase energy expenditure in hepatocytes by uncoupling mitochondrial respiration, resulting in enhanced fat oxidation, weight loss, improved insulin sensitivity, and favorable effects on lipids and liver biochemistry. Tirzepatide acts as an incretin mimetic, stimulating insulin secretion and inhibiting glucagon release. The combination aims to deliver additive or synergistic metabolic benefits, including greater weight loss and improved glycemic control than either agent alone. Clinical and preclinical results suggest that TLC-6740 complements tirzepatide by amplifying weight loss and insulin sensitization, with ongoing trials evaluating safety and efficacy in obese patients, including those with type 2 diabetes and nonalcoholic steatohepatitis (NASH)[7][9][1][5].